Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Symbicort

 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (5)

BudesonideBudesonide, Formoterol Fumarate Drug Combinationformoterolformoterol fumarate
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Study of The Fasting of Ramadan on Asthmatic Patients and The Outcome with Treatment Modification
Ramadan, the 9 th month of Islamic calendar ranging for 29-30 days in duration, during which Muslims are fasting . It was… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
2017
2017
Real-World Cost Effectiveness Comparison Of Symbicort Turbuhaler And Duoresp Spiromax In UK Patients With Asthma Or Chronic Obstructive Pulmonary Disease
Objectives: To compare economic outcomes between patients with asthma or chronic obstructive pulmonary disease (COPD) receiving… Expand
2016
2016
A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator ( CFTR) gene therapy in patients with cystic fibrosis
Background Cystic fibrosis (CF) is a chronic, life-limiting disease caused by mutations in the CF transmembrane conductance… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug.
One of the most widespread dry powder fixed combinations used in asthma and chronic obstructive pulmonary disease (COPD… Expand
2014
2014
Comparing clinical efficacy of Symbicort versus Pulmicort in reducing asthma symptom and improving its control
Background: Recently, higher efficacy of the combination of long-acting beta2-adrenoceptor agonist and inhaled corticosteroids on… Expand
  • figure 1
  • table 1
  • table 2
2013
2013
Therapeutic observation of symbicort turbuhaler in combination with montelukast on child patients with moderate and severe bronchial asthma
Objective To observe the therapeutic effectiveness of symbicort turbuhaler plus montelukast on moderate and severe bronchial… Expand
2012
2012
Observation on therapeutic effects of symbicort inhalation in thetreatment of acute mild or moderate asthma
Objective To observe the therapeutic effect and safety of Budesonide and Formoterol Fumarate inhalation(Symbicort Turbuhaler) in… Expand
Review
2008
Review
2008
Symbicort: a pharmacoeconomic review
  • D. Halpin
  • Journal of medical economics
  • 2008
    • Corpus ID: 13205367
Abstract Objective: This systematic review examines the published evidence on the pharmacoecomonics of Symbicort®*. Symbicort is… Expand
2005
2005
Fixed and adjustable dose asthma action plans based on combination therapy: A pilot study
Objective:  The use of combination inhaled corticosteroid/long‐acting β‐agonist therapy within the framework of a self‐management… Expand
Review
2002
Review
2002
Managing a variable disease.
  • J. Kips
  • Pulmonary pharmacology & therapeutics
  • 2002
    • Corpus ID: 24486330
Asthma varies in severity over time; consequently, treatment regimens must be sufficiently flexible to be adjusted when necessary… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE